Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2017-000202
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis

Scientific Reports
Multidisciplinary
2019English

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

The Impact of HER2 Phenotype of Circulating Tumor Cells in Metastatic Breast Cancer: A Retrospective Study in 107 Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2004English

Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2016English

Serum HER2 Levels Determined by Two Methods in Patients With Metastatic Breast Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy